Introduction
Immuna Therapeutics closes the divide between discovery and clinic by offering unified access to next‑generation TricarT therapies and GMP‑validated lentiviral vectors—speeding translational science, global trial rollouts, and patient access.
Seamless Access to TricarT + Process‑Validated Vector Supply
- Single partnership
- One contract, one point of contact for both therapeutic development and vector manufacturing.
- Clinical‑grade consistency
- GMP lentiviral vectors tailored for TricarT applications with validated processes and traceable QA.
- Faster translation
- Parallel development reduces qualification delays and enables immediate scale‑up.
Accelerating Clinical Deployments Across Continents
- Centralized, scalable manufacturing
- Consistent quality from Switzerland for multi‑site trials.
- Simplified regulatory paths
- Unified documentation and support ease multi‑region submissions.
- Reliable supply chain
- Continuous vector supply and coordinated logistics speed trial expansion.
Improving Affordability and Patient Access
- Lower development costs
- Elimination of duplicated systems and vendor overhead reduces total program spend.
- Scalable production
- Efficiency gains lower per‑patient manufacturing costs.
- Broader reach
- Faster, cheaper pathways make advanced therapies more accessible in diverse markets.
Conclusion
By combining TricarT innovation with process‑validated GMP manufacturing under one roof, Immuna accelerates bench‑to‑bedside timelines, reduces costs, and expands patient access—making translational science more practical and impactful.
